Active	Status	Sponsor type	Region	Phase	Filter
4 Active 7 Inactive 11 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other Show only owner-sponsored trials	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
volagidemab (REMD-477) / Amgen, REMD Bio
NCT04779645: Effects of GRA in Patients With Type 1	Active, not recruiting	2	30	US	REMD-477, Placebo	University of California, San Diego, REMD Biotherapeutics, Inc.	Type 1 Diabetes	12/24	03/25
SOTA, NCT05696366: Combination Adjunctive Therapy to Address Multiple Metabolic Imbalances in Type 1 Diabetes	Recruiting	1/2	24	US	Sotagliflozin, Volagidemab	University of California, San Diego, Lexicon Pharmaceuticals, Breakthrough T1D	Type 1 Diabetes	01/28	01/28
NCT06272695: Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab	Recruiting	1	24	US	Volagidemab	REMD Biotherapeutics, Inc.	Type 1 Diabetes Mellitus	06/25	06/25
NCT05093517: Effect of Novel Glucagon Receptor Antagonist REMD-477 on Glucose and Adipocyte Metabolism in T2DM	Completed	1	4	US	REMD-477, Placebo Subcutaneous injection, Placebo	The University of Texas Health Science Center at San Antonio	Type 2 Diabetes, Glucose Tolerance Impaired, Insulin Sensitivity	03/22	03/22